Status:
COMPLETED
LEAVE Safe With DOACs
Lead Sponsor:
University of Massachusetts, Worcester
Collaborating Sponsors:
Agency for Healthcare Research and Quality (AHRQ)
Conditions:
Cardiovascular Diseases
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Given the risks associated with direct oral anticoagulants (DOACs) and the lack of defined pathways for patients prescribed this class of medications, the study intervention has the potential for an e...
Detailed Description
Patients first treated with direct oral anticoagulants (DOACs) in an ambulatory setting are at an elevated risk for adverse drug events (ADEs) or potential ADEs from medication errors. An intervention...
Eligibility Criteria
Inclusion
- Age ≥ 18
- New prescription of DOAC within 4 days of consent OR continued DOAC use for a patient with new episode of worsening thromboembolic or bleeding event within 4 days of consent or discharged from the hospital with DOAC prescription within 4 days of consent
- Fluency in English, Portuguese, or Spanish
Exclusion
- Currently hospitalized with inpatient status (as opposed to observation status)
- Age \< 18
- Prisoners
- Pregnant patients (medications are contraindicated)
Key Trial Info
Start Date :
December 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 14 2022
Estimated Enrollment :
561 Patients enrolled
Trial Details
Trial ID
NCT04068727
Start Date
December 2 2019
End Date
September 14 2022
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMass Memorial Medical Center
Worcester, Massachusetts, United States, 01605